Phase I Trial of HR070803 (an Irinotecan Liposome) in Combination With 5-Fluorouracil, Leucovorin, and Oxaliplatin for Untreated Advanced, or Metastatic Pancreatic Ductal Adenocarcinoma

Investigators assessed the safety, preliminary antitumor activity, and pharmacokinetics of HR070803 in combination with 5-FU/LV and oxaliplatin for treatment-naive patients with unresectable locally advanced or metastatic PDAC.